Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia

Norazida Ab Rahman; Ming Tsuey Lim; Fei Yee Lee; Emelyne Bani Anak Jam; Kalaiarasu M Peariasamy; Sheamini Sivasampu; SAFECOVAC study group

doi:10.1016/j.jvacx.2023.100303

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia

Vaccine X. 2023 Aug:14:100303. doi: 10.1016/j.jvacx.2023.100303. Epub 2023 Apr 15.

Authors

Norazida Ab Rahman¹, Ming Tsuey Lim¹, Fei Yee Lee², Emelyne Bani Anak Jam³, Kalaiarasu M Peariasamy¹, Sheamini Sivasampu¹; SAFECOVAC study group

Affiliations

¹ Institute for Clinical Research, National Institutes of Health, Selangor, Malaysia.
² Clinical Research Centre, Selayang Hospital, Ministry of Health, Selangor, Malaysia.
³ Clinical Research Centre, Queen Elizabeth II Hospital, Ministry of Health, Sabah, Malaysia.

Abstract

This study evaluates 21-day risk of myocarditis/pericarditis following COVID-19 vaccination among those aged 12 years and older in Malaysia. We used data from nationwide COVID-19 vaccine registry linked to hospital episode database to identify individuals vaccinated with BNT162b2, CoronaVac, or ChAdOx1 and hospitalised for myocarditis/pericarditis between 1 February 2021 and 28 February 2022. There were 87 myocarditis/pericarditis cases identified within 1-21 days after vaccination. Most cases were reported following BNT16262 vaccination (77.0%) with absolute risk of 0.33 cases/100,000 vaccinated persons or 1.73 per million doses administered. Highest risk was observed following second dose and in younger, male individuals. The risk of myocarditis/pericarditis following CoronaVac and ChAdOx1 were much lower compared to BNT162b2. The findings on higher risk observed among younger following mRNA vaccine were consistent with literature and important for targeted surveillance.

Keywords: Adverse effects; COVID-19 vaccine; Myocarditis; Pericarditis.